Related Experiment Video

Updated: Aug 22, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Fluvastatin and fluvastatin extended release: a clinical and safety profile

Anders Asberg1, Hallvard Holdaas

  • 1Medical Department, National Hospital, Oslo, Norway. anders.asberg@farmasi.uio.no

Expert Review of Cardiovascular Therapy
|September 8, 2004
PubMed

Insights

Fluvastatin, a synthetic cholesterol-lowering drug, effectively reduces cardiovascular risks. Its safety profile may stem from its primary acid form and metabolism via cytochrome P450 2C9.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Metabolism

Background:

  • Cardiovascular diseases (CVDs) driven by atherosclerosis are a major global health concern.
  • Statins, including fluvastatin, are crucial for lowering cholesterol and reducing CVD morbidity and mortality.
  • Fluvastatin was the first synthetic statin and is now available in an extended-release form (Lescol XL).

Purpose of the Study:

  • To review the clinical benefits and safety profile of fluvastatin.
  • To explore the pharmacokinetic properties contributing to fluvastatin's safety.

Main Methods:

  • Analysis of data from clinical outcome trials involving fluvastatin.
  • Review of fluvastatin's in vivo form and metabolic pathways.

Main Results:

  • Fluvastatin has demonstrated significant cardiovascular benefits across diverse patient populations.
  • The drug is predominantly present as its inactive acid form in vivo.
  • Fluvastatin is primarily metabolized by the cytochrome P450 2C9 enzyme.

Conclusions:

  • Fluvastatin is a safe and effective option for cholesterol-lowering therapy.
  • Its safety may be attributed to its predominant acid form and specific metabolic pathway, minimizing active metabolite formation.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...